MedTrace Logo

Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease

NCT04749563 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-09-16

No results posted yet for this study

Summary

A single center, randomized, placebo controlled multiple ascending dose study of IGC AD1 to evaluate safety and tolerability in subjects with dementia due to Alzheimer's Disease (AD).

Conditions

  • Dementia of Alzheimer Type

Interventions

DRUG

IGC AD1

IGC AD1 oral Solution

DRUG

Placebo

Placebo of IGC AD1 oral Solution

Sponsors & Collaborators

  • IGC Pharma, LLC

    lead INDUSTRY

Principal Investigators

  • IGC Pharma INC · IGC Pharma INC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
60 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-11
Primary Completion
2021-06-20
Completion
2021-06-20
FDA Drug
Yes

Countries

  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04749563 on ClinicalTrials.gov